Themis Medicare Ltd. (BSE: 530199) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹941 Cr, it ranks #1,624 by market cap among the 6,197 Indian listed companies on FinBizNet, and #48 of 86 in Medicinal Chemicals and Botanical Products. At ₹102.00 (as of 16 Nov 2026), the share price is 27.5% below its 52-week high of ₹140.60 and 57.0% above its 52-week low of ₹64.95. The share price is down 13.1% over one year and down 2.9% over three months.
| Current Price | ₹102.00 |
|---|---|
| Market Cap | ₹941 Cr |
| BSE Code | 530199 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 854.8 |
| Return on Equity | 0.29% |
| Return on Assets | -1.05% |
| 52-Week Range | ₹64.95 – ₹140.60 |
| 1-Year Price Change | -13.1% |
| 3-Month Price Change | -2.9% |
| Beta (1Y) | 0.4 |
| Dividend Yield | 0.49% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.themismedicare.com |
| Revenue | ₹90 Cr |
|---|---|
| Net Profit | ₹7 Cr |
| Net Margin | 7.9% |
| EPS (Basic) | ₹0.77 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Themis Medicare Ltd. reported revenue of ₹90 Cr in Q2 FY27, up 15.1% from ₹78 Cr in Q2 FY26 and up 3.2% from ₹87 Cr in Q1 FY27. It posted a net profit of ₹7 Cr for the quarter, against a net loss of ₹4 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹72 Cr (Q4 FY25) to ₹98 Cr (Q1 FY26). The company reported a net loss in 3 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹90 Cr | ₹7 Cr | 7.9% |
| Q1 FY27 | ₹87 Cr | ₹25 Cr | 28.3% |
| Q4 FY26 | ₹77 Cr | ₹9 Cr | 11.6% |
| Q3 FY26 | ₹90 Cr | ₹10 Cr | 11.2% |
| Q2 FY26 | ₹78 Cr | −₹4 Cr | −4.6% |
| Q1 FY26 | ₹98 Cr | −₹14 Cr | −14.6% |
| Q4 FY25 | ₹72 Cr | −₹10 Cr | −13.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 67.11% of Themis Medicare Ltd.'s shares as of Sept 2026, against 67.15% in Sept 2025 (−0.04 percentage points). Delivery averaged 46.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, hematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasodilator, vasopr
1. Pharmaceuticals-This segment manufactures and sells pharmaceutical products. It offers active pharmaceutical ingredients and formulations for use in various therapeutic areas, such as anti-infective, antimalarial, anti-tuberculosis, cardiology, health and nutrition, oncology, ophthalmology, and pain management.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Themis Medicare Ltd. | ₹941 Cr | 854.8 | 0.29% | ₹90 Cr | -13.1% |
Listed by market capitalisation. Ratios are shown for context only.
Themis Medicare Ltd. is trading at ₹102.00, with a market capitalisation of ₹941 Cr.
Themis Medicare Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Themis Medicare Ltd. has a P/E of 854.8 and a return on equity of 0.29%.
Themis Medicare Ltd. is listed on the BSE under the scrip code 530199.
Themis Medicare Ltd.'s share price is down 13.1% over one year and down 2.9% over three months. Its 52-week range is ₹64.95 to ₹140.60.
In Q2 FY27, Themis Medicare Ltd. reported revenue of ₹90 Cr and net profit of ₹7 Cr, with basic EPS of ₹0.77 (consolidated, parsed from the company's exchange filing).
Themis Medicare Ltd. reported revenue of ₹90 Cr in Q2 FY27, up 15.1% from ₹78 Cr in Q2 FY26 and up 3.2% from ₹87 Cr in Q1 FY27.
Promoters held 67.11% of Themis Medicare Ltd.'s shares as of Sept 2026, against 67.15% in Sept 2025 (−0.04 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.